NCT04899505Completed
Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology
ODORAJA:Evaluation of the Impact of Chemotherapy on Body Odor in Adolescents and Young Adults in Oncology
Source: ClinicalTrials.gov · Last updated 16 May 2025
Brief summary (registry, in English)
The appearance of unpleasant body odors in adolescent Young adult (aya) wille be evaluated undergoing chemotherapy
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 27 (actual)
- First submitted
- 19 May 2021
- Start date
- 21 Oct 2021
- Primary completion date
- 12 May 2025
- Lead sponsor
- Institut Curie
- Diseases
- Childhood cancers
- NCT number
- NCT04899505
What you commit to
- Study type: Observational
- Participants enrolled: 27
- From 21 Oct 2021 to the primary completion date, 12 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patient undergoing oral chemotherapy;
Other
- Persons deprived of their liberty or under guardianship (including guardianship);
- Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.
Who the study is looking for
- Patients aged between 15 and 25 years;
- New patients treated at the Curie Institute and hospitalized in the AJA oncology department;
- Patient undergoing chemotherapy administered intravenously;
- Solid tumors.
Age in the registry: 15 years to 25 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut Curie Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.